Disclosures for "Efficacy and Predictors of Discontinuation of Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion Therapy in a Parkinson’s Disease Cohort"
-
Dr. Malfer has nothing to disclose.
-
Miss Santoro has nothing to disclose.
-
Dr. Ali has nothing to disclose.
-
The institution of Dr. Savica has received research support from ACADIA Pharmaceuticals, Inc.